Shionogi & Co. Ltd. announced that Shionogi and StemRIM Inc. (Headquarters: Ibaraki City, Osaka; Chairman and CEO: Kensuke Tomita; hereinafter "StemRIM") have entered into a new license agreement for S-005151 [Generic name: Redasemtide] to conduct investigator-initiated clinical studies targeting new indications in the future. This license agreement enables Shionogi to utilize the evidence of non-clinical research that has been accumulated by StemRIM through joint research with several academia groups. Shionogi and StemRIM will promote investigator-initiated clinical studies for three new indications (chronic liver disease, knee osteoarthritis, and cardiomyopathy).